WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The product will be manufactured at Lupin’s facility in Goa, India.
New deal strengthens Congenica’s presence in India
Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Subscribe To Our Newsletter & Stay Updated
